VC
ACTU

Voss Capital’s Actuate Therapeutics ACTU Stock Holding History

Voss Capital’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.73M Buy
1,725,000
+425,000
+33% +$1.76M 0.25% 37
2025
Q4 		$7.96M Buy
1,300,000
+403,722
+45% +$2.77M 0.38% 33
2025
Q3 		$6M Buy
896,278
+610,138
+213% +$4.42M 0.3% 36
2025
Q2 		$1.75M Buy
286,140
+143,759
+101% +$1.26M 0.12% 44
2025
Q1 		$964K Buy
142,381
+87,135
+158% +$700K 0.07% 51
2024
Q4 		$440K Buy
+55,246
New +$451K 0.03% 42

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Voss Capital's ACTU Position: Q1 2026 in Review

Voss Capital increased its Actuate Therapeutics (ACTU) stake by 33% in Q1 2026, buying an estimated $1.76M and bringing the position to 1,725,000 shares worth $4.73M. The position accounts for 0.25% of the portfolio, ranked #37.

Voss Capital first reported a position in ACTU in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.96M in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Voss Capital held 1,725,000 shares of Actuate Therapeutics worth $4.73M as of Q1 2026.
  • Voss Capital bought 425,000 Actuate Therapeutics shares in Q1 2026, an estimated $1.76M.
  • Actuate Therapeutics made up 0.25% of Voss Capital's portfolio in Q1 2026, its #37 holding.
  • Voss Capital first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Voss Capital's Actuate Therapeutics position peaked at $7.96M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Voss Capital's 13F filing for Q1 2026, filed 15 May 2026.